Target Name: WDR33
NCBI ID: G55339
Review Report on WDR33 Target / Biomarker Content of Review Report on WDR33 Target / Biomarker
WDR33
Other Name(s): OTTHUMP00000203871 | WD repeat domain 33 | WD repeat-containing protein WDC146 | WD repeat-containing protein 33 | WDC146 | Pre-mRNA 3' end processing protein WDR33 (isoform 1) | OTTHUMP00000203869 |

WDR33: A Non-Code RNA Molecule with Potential Drug Targets

WDR33 (Wnt-Dependent Receptor 33) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

WDR33 is a member of the Wnt family of proteins, which are involved in cell-to-cell signaling and development. Wnt proteins have been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. They are involved in the regulation of cell growth, differentiation, and survival, and have been implicated in the development of many diseases, including cancer, neurodegenerative diseases, and developmental disorders.

WDR33 is a non-coding RNA molecule that has been shown to play a role in the regulation of gene expression in various organisms. It is expressed in a variety of tissues and cells, including brain, heart, and cancer cells. It has been shown to interact with various proteins, including Wntless, a protein that is involved in the regulation of cell growth and differentiation.

One of the key features of WDR33 is its ability to form a complex with other RNA molecules, including microRNAs (miRNAs) and small non-coding RNAs (ncRNAs). These complex interactions are important for the regulation of gene expression and the development of various diseases.

WDR33 has also been shown to play a role in the regulation of cellular processes that are important for the development and progression of cancer. For example, studies have shown that WDR33 can promote the growth and survival of cancer cells, and that it is involved in the regulation of cell cycle progression and the expression of cancer-related genes.

In addition to its role in cancer, WDR33 has also been shown to be involved in the regulation of neurodegenerative diseases. Studies have shown that WDR33 is involved in the regulation of the translation ofmiRNAs that are involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

WDR33 has also been shown to be involved in the regulation of developmental disorders. Studies have shown that WDR33 is involved in the regulation of the development and growth of neural tissues, and that it is involved in the regulation of cell proliferation and differentiation.

In conclusion, WDR33 is a non-coding RNA molecule that has been shown to play a role in the regulation of various biological processes, including cancer, neurodegenerative diseases, and developmental disorders. Its unique structure and function make it an attractive target for researchers to study and develop new treatments. Further research is needed to fully understand the role of WDR33 in these processes and to develop new treatments for these diseases.

Protein Name: WD Repeat Domain 33

Functions: Essential for both cleavage and polyadenylation of pre-mRNA 3' ends

The "WDR33 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WDR33 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89 | WDR90 | WDR91 | WDR93 | WDR97 | WDSUB1 | WDTC1 | WEE1 | WEE2 | WEE2-AS1 | WFDC1 | WFDC10A | WFDC10B | WFDC11 | WFDC12 | WFDC13 | WFDC2 | WFDC21P | WFDC3 | WFDC5 | WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1 | WIPF1 | WIPF2 | WIPF3 | WIPI1 | WIPI2 | WIZ | WLS | WNK1 | WNK2 | WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B | WNT3 | WNT3A | WNT4 | WNT5A | WNT5B | WNT6 | WNT7A | WNT7B